Tirzepatide in South Africa: How It Works, Results and Cost

If semaglutide (the ingredient in Ozempic and Wegovy) has dominated weight loss conversations for the past two years, tirzepatide is the next chapter. Sold in South Africa as Mounjaro, tirzepatide is the first weight loss injection to target two gut hormones simultaneously — and clinical trial data suggests it produces greater weight loss than any previous injectable therapy. This guide covers how tirzepatide works, what results to realistically expect, what it costs locally, and how it compares to semaglutide.

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Where semaglutide activates only the GLP-1 (glucagon-like peptide-1) receptor, tirzepatide activates two receptors simultaneously:

• GLP-1 receptor — suppresses appetite, slows stomach emptying, stimulates insulin release
• GIP receptor (glucose-dependent insulinotropic polypeptide) — improves insulin sensitivity, enhances fat burning, and appears to amplify the appetite-suppressing effects of GLP-1

This dual action is the key reason tirzepatide's trial results consistently outpace single-receptor GLP-1 drugs like semaglutide and liraglutide (Saxenda). It is administered as a once-weekly subcutaneous injection, starting at 2.5 mg and stepping up every four weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg depending on response and tolerability.

SURMOUNT Trial Results: What the Science Shows

Tirzepatide's weight loss credentials come primarily from the SURMOUNT phase 3 trial programme, which enrolled thousands of adults with obesity or overweight-plus-comorbidities over 72 weeks.

SURMOUNT-1 (non-diabetic adults)

• 5 mg dose: average 15% body weight loss
• 10 mg dose: average 19.5% body weight loss
• 15 mg dose: average 20.9% body weight loss — roughly 22 kg for a 105 kg person
• Placebo: 3.1% weight loss

To put that in context: a 90 kg South African adult starting at the highest dose could realistically lose 18-20 kg over 72 weeks while maintaining lean mass — provided they make dietary and lifestyle changes alongside the medication.

SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head

Published in 2025, SURMOUNT-5 directly compared tirzepatide 10 mg/15 mg against semaglutide 2.4 mg (Wegovy) in adults with obesity. Tirzepatide produced approximately 47% greater relative weight loss than semaglutide — a clinically meaningful difference. This was the first large randomised head-to-head trial, and the results cemented tirzepatide's position as the highest-efficacy injectable currently available in South Africa.

Tirzepatide vs Semaglutide: Key Differences

Both drugs are weekly injections that dramatically reduce appetite — but there are important differences to discuss with your doctor:

Note: pricing is approximate and varies by dose, pharmacy, and private medical aid coverage. Always verify current pricing with your dispensing pharmacy.

Tirzepatide Availability and Cost in South Africa

Mounjaro (tirzepatide) is registered in South Africa for the treatment of type 2 diabetes. Doctors may prescribe it off-label for weight management in patients with obesity, which is standard practice for many GLP-1 class medications locally. The obesity-specific brand Zepbound has not been registered with SAHPRA at time of writing.

Approximate monthly costs at South African private pharmacies (2026):

• 2.5 mg (starter dose): R2,500 - R3,000/month
• 5 mg: R3,000 - R3,800/month
• 10 mg: R4,000 - R4,800/month
• 15 mg (maintenance): R4,500 - R5,200/month

Medical aids vary widely on coverage. Discovery Health's Managed Care programme covers GLP-1 class medications for qualifying diabetic members; obesity-specific coverage is less consistent — check your plan details directly. See our full breakdown on Mounjaro cost in South Africa.

Side Effects: What to Expect

Tirzepatide's side effect profile is similar to semaglutide — most are gastrointestinal and tend to ease as your body adjusts to each dose increase:

• Nausea — most common, especially in the first 4-8 weeks at each dose step. Eating smaller, lower-fat meals helps significantly.
• Vomiting and diarrhoea — less common than nausea but reported by some patients; usually transient.
• Constipation — can develop as gastric emptying slows. Staying hydrated and eating high-fibre foods (roasted vegetables, legumes, and rooibos-steeped barley) helps.
• Injection site reactions — mild redness or swelling; rotate injection sites to reduce this.
• Fatigue — some users report low energy in the first weeks, often linked to reduced calorie intake rather than the drug itself.

Rare but serious risks include pancreatitis and gallbladder disease. There is also a theoretical risk of thyroid C-cell tumours based on rodent studies — the drug carries a boxed warning and should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Who Is a Candidate for Tirzepatide?

Your doctor will assess you against the following general criteria, which align with SURMOUNT trial inclusion standards and South African prescribing norms:

• BMI of 30 or above (obesity); or BMI 27+ with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or type 2 diabetes
• Previous genuine attempts at diet and lifestyle changes without sustained results
• No personal or family history of MTC or MEN2
• Not pregnant or planning pregnancy
• No severe gastrointestinal conditions (e.g. gastroparesis)

Tirzepatide tends to be considered when semaglutide has been tried without adequate response, or when the clinical picture suggests the dual GIP/GLP-1 mechanism will be more effective — for example, patients with significant insulin resistance often respond particularly well to the GIP component.

Practical Tips for Starting Tirzepatide in SA

• Find a doctor experienced with GLP-1 therapy — most endocrinologists, bariatric physicians, and an increasing number of GP practices are familiar with Mounjaro prescribing.
• Start low, go slow — the 2.5 mg starter dose exists for a reason. Rushing to higher doses increases side effects without necessarily accelerating weight loss.
• Pair it with protein — aim for at least 1.2 g protein per kg body weight per day. Biltong, eggs, legumes, and low-fat dairy are excellent SA-friendly sources. See our protein diet guide.
• Keep injections consistent — pick the same day each week. Store pens in the fridge; do not freeze.
• Track non-scale victories — clothes fit, blood pressure, energy levels, and blood sugar improvements often appear weeks before the scale reflects your progress.

The Bottom Line

Tirzepatide is the most effective injectable weight loss medication currently available in South Africa, backed by some of the most compelling clinical trial data in obesity medicine history. SURMOUNT-1 showed average losses of nearly 21% of body weight at the highest dose — and head-to-head data confirms it outperforms semaglutide. It is not cheap and it is not a quick fix: it works best as part of a sustained lifestyle programme, and weight typically returns if the drug is discontinued without maintaining the dietary habits built during treatment.

If you think tirzepatide might be right for you, the next step is a consultation with a doctor who can review your full health picture, confirm there are no contraindications, and write a prescription for Mounjaro. See our related guides on Mounjaro weight loss results, semaglutide in South Africa, and the full weight loss injection comparison.